- Home
- ADAG vs SAVA Comparison
ADAG vs SAVA Comparison
Compare ADAG & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAG
- SAVA
- Stock Information
- Founded
- ADAG 2011
- SAVA 1998
- Country
- ADAG China
- SAVA United States
- Employees
- ADAG N/A
- SAVA N/A
- Industry
- ADAG Biotechnology: Pharmaceutical Preparations
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- ADAG Health Care
- SAVA Health Care
- Exchange
- ADAG Nasdaq
- SAVA Nasdaq
- Market Cap
- ADAG 110.8M
- SAVA 102.4M
- IPO Year
- ADAG 2021
- SAVA N/A
- Fundamental
- Price
- ADAG $1.95
- SAVA $3.48
- Analyst Decision
- ADAG Strong Buy
- SAVA Buy
- Analyst Count
- ADAG 3
- SAVA 2
- Target Price
- ADAG $7.67
- SAVA $5.00
- AVG Volume (30 Days)
- ADAG 60.8K
- SAVA 5.1M
- Earning Date
- ADAG 08-12-2025
- SAVA 11-06-2025
- Dividend Yield
- ADAG N/A
- SAVA N/A
- EPS Growth
- ADAG N/A
- SAVA N/A
- EPS
- ADAG N/A
- SAVA N/A
- Revenue
- ADAG $103,204.00
- SAVA N/A
- Revenue This Year
- ADAG $7,411.34
- SAVA N/A
- Revenue Next Year
- ADAG $28.29
- SAVA N/A
- P/E Ratio
- ADAG N/A
- SAVA N/A
- Revenue Growth
- ADAG N/A
- SAVA N/A
- 52 Week Low
- ADAG $1.33
- SAVA $1.15
- 52 Week High
- ADAG $3.16
- SAVA $33.98
- Technical
- Relative Strength Index (RSI)
- ADAG 44.56
- SAVA 66.55
- Support Level
- ADAG $1.85
- SAVA $2.85
- Resistance Level
- ADAG $2.06
- SAVA $3.84
- Average True Range (ATR)
- ADAG 0.11
- SAVA 0.36
- MACD
- ADAG -0.01
- SAVA 0.08
- Stochastic Oscillator
- ADAG 26.08
- SAVA 79.08
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.